Fig. 1 Minimum surface tension (ST; γmin) of Survanta at concentration 2.5 mg/ml (a), 3 mg/ml (b), 4 mg/ml (c), and 5 mg/ml (d) with or without rifampicin (RIF) 1, 5, and 10 % (w/w)…
Moderate OSA Group A (n = 15) Severe OSA Group B (n = 15) Control Group C (n = 20) p <0.05 Age (years) 59.6 ± 6.5 54.5 ± 8.9 47.0 ± 12.4 C vs. A BMI (kg/m2) 30.7 ± 2.5 32.2 ± 5.5 27.0 ± 3.5 B…
Inclusion criteria Age between 8 and 17 years Children with diagnosed asthma, confirmed by spirometry Children treated with inhaled corticosteroids continuously for at least 4 years The time without treatment…
Serum sCD40L r-Spearman’s p Age 0.12 ns BMI 0.16 ns AHI 0.24 0.01 DI 0.17 ns Mean SaO2 −0.13 ns Mean of min. SaO2 −0.18 <0.05 CRP 0.21 <0.05…
© Springer International Publishing Switzerland 2014Mieczyslaw Pokorski (ed.)Inflammatory DisordersAdvances in Experimental Medicine and Biology83910.1007/5584_2014_27 Stem Cell Experiments Moves into Clinic: New Hope for Children with Bronchopulmonary Dysplasia K. Pawelec1, 2 , D. Gładysz1 , U. Demkow3 and D. Boruczkowski1…
No. of subjects 37 Male/female 11/26 Age (years; mean and range) 70 ± 8.2 (53–88) Number of exacerbation last year 0.8 (0–5) BMI (kg/m2) 28.1 (20.3–49.4) Lung function FEV1% pred. 53.9…
Target cells Type of action Airway epithelial cells Inhibition of: Chloride secretion Mucus secretion Adhesion molecules Pro-inflammatory cytokines Inflammatory mediators Enhancement of: Tight junction or cell barrier Defensin Neutrophils Inhibition…
F F + T Lymphocytes Total CD3+ 68 ± 7 70 ± 9 CD3+HLA-DR+ 11 ± 2 5 ± 3** T CD4+ 51 ± 6 62 ± 6 CD4+HLA-DR+ 11 ± 3 7 ± 1* CD8+ 10 ± 7 3 ± 1** CD8+HLA-DR+ 24 ± 13 4 ± 2** B CD19+ 13 ± 7 15 ± 6 CD19+HLA-DR+ 12 ± 5…
Fig. 1 Representative histograms of sputum cells from COPD patients. CD14 expression was used for gating macrophages and neutrophils (circle, a). Siglec-5/14 expression (b) in patients treated with LABA (thin…
